Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms 6Thyroid Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Pleural Effusion 2Ovarian Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Pemetrexed 10Cisplatin 9Gemcitabine 8Nivolumab 5Ipilimumab 4Carboplatin 4niraparib 3durvalumab 3Vinorelbine 3Bevacizumab 3tremelimumab 2pembrolizumab 2olaparib 2anetumab ravtansine 2Radiotherapy, Intensity-Modulated 2Oxaliplatin 2Imatinib Mesylate 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Cytoreduction Surgical Procedures 2vandetanib 1tislelizumab 1tazemetostat 1spartalizumab 1sargramostim 1ribociclib 1fludarabine phosphate 1fludarabine 1dostarlimab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma × vandetanib × Clear all
NCT00597116 2016-10-10

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Sanofi

Phase 2 Terminated
25 enrolled 8 charts
Other solid neoplasmThoracic

Mesothelioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡